US4954350A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Pharmaceutical formulations containing acrivastine
Assignee: SmithKline Beecham Corp
•
Filing: 1989-05-15
•
Granted: 1990-09-04
•
Expires: 2009-05-15
Abstract
Abstract The invention relates to a controlled release pharmaceutical formulation for oral administration which comprises discrete units comprising acrivastine or a salt thereof coated with a mixture containing: (a) a copolymer or polymer containing repeating monomer units selected from alkyl esters of acrylic and methacrylic acids and (b) ethyl cellulose, and a process for preparing such formulations.
Inventors
- 👤 Harry P. Jones
- 👤 Robert J. Mackey
- 👤 Michael J. D. Gamlen
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 03:30
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/48; A61K9/50; A61K9/5073; A61K9/5078; A61K31/00; A61K31/33; A61K31/395; A61K31/435; A61K31/44; A61P; A61P37/00; A61P37/08; A61P43/00
Claims Analysis
Total Claims: 13
Claim 1
Independent Claim
49 words
A controlled release pharmaceutical formulation for oral administration which comprises discrete units comprising acrivastine or a pharmacologically and pharmaceutically acceptable salt thereof coated with a mixture containing: (a) a copolymer or polymer containing repeating monomer units selected from alkyl esters of acrylic and methacrylic acids and (b) ethyl cellulose.
Claim 2
Dependent Claim
49 words
A controlled release pharmaceutical formulation for oral administration which comprises discrete units comprising acrivastine or a pharmacologically and pharmaceutically acceptable salt thereof coated with a mixture containing: (a) a copolymer or polymer containing repeating monomer units selected from alkyl esters of acrylic and methacrylic acids and (b) ethyl cellulose.
Claim 3
Dependent Claim
26 words
A formulation according to claim 1 where coating component (a) is a copolymer of one or more C 1-4 alkyl esters of acrylic or methacrylic acid.
Claim 4
Dependent Claim
19 words
A formulation according to claim 2 wherein the co-polymer has an average molecular weight of between 100,000 and 950,000.
Claim 5
Dependent Claim
24 words
A formulation according to claim 1 wherein components (a) and (b) are present in the coating in a weight ratio of 2:1 to 1:2.
Claim 6
Dependent Claim
23 words
A formulation according to claim 1 wherein the components (a) and (b) are present in the coating in a weight ratio of 1:1.
Claim 7
Dependent Claim
24 words
A formulation according to claim 1 wherein the coating contains between 5 and 40% of an agent for modifying the porosity of the coating.
Claim 8
Dependent Claim
18 words
A formulation according to claim 6 wherein the agent for modifying the porosity of the coating is mannitol.
Claim 9
Dependent Claim
14 words
A formulation according to claim 1 wherein acrivastine is present as a hydrochloride salt.
Claim 10
Dependent Claim
17 words
A formulation according to claim 1 wherein the coated discrete units are presented in unit dose form.
Claim 11
Dependent Claim
18 words
A formulation according to claim 9 wherein the coated discrete units are admixed with a further therapeutic agent.
Claim 12
Dependent Claim
13 words
A formulation according to claim 10 wherein the further therapeutic agent is pseudoephedrine.
Claim 13
Dependent Claim
48 words
A process for preparing a formulation according to claim 1 which comprises applying to discrete units comprising acrivastine or a salt thereof a coating mixture containing (a) a polymer or copolymer containing repeating monomer units selected from alkyl esters of acrylic and methacrylic acids and (b) ethyl cellulose.
References Cited (Backward Citations)
GB2087235A
Cited
GB2086725A
Cited
EP0085959A2
Cited
US4501893A
Cited
US4650807A
Cited
EP0142877A2
Cited
WO1985003436A1
Cited
WO1985003437A1
Cited
GB2157170A
Cited
US4871733A
Cited
EP0202051A2
Cited
EP0205336A2
Cited
GB2178313A
Cited
GB2180154A
Cited
WO1987001588A1
Cited
US4693896A
Cited
WO1987002240A1
Cited
EP0226884A2
Cited
EP0248447A2
Cited
EP0249949A2
Cited
EP0250267A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-09-03 | 1994-03-05 | 1994-09-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-09-03 | 1998-03-05 | 1998-09-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-09-03 | 2002-03-05 | 2002-09-04 | $7700.00 | Window Closed / Lapsed |